Capivasertib联合紫杉醇一线治疗转移性三阴性乳腺癌:III期CAPItello-290研究结果
CAPItello-290是一项随机、全球III期试验,评估Capivasertib联合紫杉醇对比安慰剂联合紫杉醇一线治疗转移性三阴性乳腺癌。共随机812例患者,30.7%存在PIK3CA/AKT1/PTEN改变。最终分析显示,联合治疗未达到预设的OS改善边界,总人群和PIK3CA/AKT1/PTEN改变人群的OS均无显著获益;PFS数值上支持联合治疗。安全性总体可控。
要点
- Capivasertib联合紫杉醇一线治疗转移性TNBC未显著改善OS。
- PIK3CA/AKT1/PTEN改变亚组中OS同样无获益。
- PFS数值上支持联合治疗,尤其在PIK3CA/AKT1/PTEN改变患者中。
核心结论
- Capivasertib联合紫杉醇未达到预设的OS改善边界,总人群和PIK3CA/AKT1/PTEN改变人群均无OS显著获益。
- PFS在数值上倾向于联合治疗,尤其在PIK3CA/AKT1/PTEN改变患者中。
- 安全性总体可控,与既往研究一致。
研究设计与样本
- 随机、全球、III期试验,纳入既往未治疗的转移性三阴性乳腺癌患者。
- 患者按1:1随机接受紫杉醇80 mg/m²(第1天,第1-3周,4周周期)联合Capivasertib 400 mg或安慰剂每日两次(第2-5天,第1-3周)。
- PIK3CA/AKT1/PTEN改变通过回顾性中心分子检测分析。
- 双主要终点为总人群和PIK3CA/AKT1/PTEN改变患者的OS;研究者评估的PFS为关键次要终点。
- 2019年7月至2022年2月共随机812例患者;30.7%存在PIK3CA/AKT1/PTEN改变。
主要发现
- 最终分析(数据截止2024年3月18日)显示,总人群中Capivasertib联合紫杉醇组与安慰剂联合紫杉醇组的中位OS分别为17.7个月和18.0个月(HR 0.92,95%CI 0.78-1.08,P=0.3239)。
- PIK3CA/AKT1/PTEN改变患者中,两组中位OS均为20.4个月(HR 1.05,95%CI 0.77-1.43,P=0.7602)。
- PFS数据截止2022年5月25日,总人群中位PFS分别为5.6个月和5.1个月(HR 0.72,95%CI 0.61-0.84)。
- PIK3CA/AKT1/PTEN改变患者中位PFS分别为7.5个月和5.6个月(HR 0.70,95%CI 0.52-0.95)。
- 总人群中≥3级最常见不良事件为腹泻(12.7% vs 0.7%)。
关键数值与推荐
- 总人群OS:HR 0.92(95%CI 0.78-1.08),P=0.3239。
- PIK3CA/AKT1/PTEN改变人群OS:HR 1.05(95%CI 0.77-1.43),P=0.7602。
- 总人群PFS:HR 0.72(95%CI 0.61-0.84)。
- PIK3CA/AKT1/PTEN改变人群PFS:HR 0.70(95%CI 0.52-0.95)。
- 因不良事件停药率:Capivasertib组8.5%,安慰剂组4.9%(总人群)。
临床怎么用
- 对于既往未治疗的转移性TNBC,Capivasertib联合紫杉醇未显示OS获益,不推荐作为一线标准治疗。
- PIK3CA/AKT1/PTEN改变状态不能用于筛选从Capivasertib联合紫杉醇中OS获益的患者。
- 联合治疗PFS数值获益需进一步验证,临床决策应综合考虑疗效与安全性。
局限性
- PIK3CA/AKT1/PTEN改变为回顾性中心检测,可能存在检测偏倚。
- PFS分析基于较早的数据截止日期(2022年5月25日),而OS分析基于最终数据截止(2024年3月18日)。
- 未报告其他亚组或敏感性分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adding the pan-Akt serine/threonine kinase (AKT) inhibitor capivasertib to first-line paclitaxel in metastatic triple-negative breast cancer (TNBC) led to significantly longer progression-free survival (PFS) and overall survival (OS) versus placebo-paclitaxel in the phase II PAKT trial. CAPItello-290 was designed to further assess capivasertib-paclitaxel, including in patients with PIK3CA/AKT1/PTEN-altered tumours. PATIENTS AND METHODS: Patients with previously untreated metastatic TNBC were randomised 1 : 1 to paclitaxel 80 mg/m2 [day 1, weeks 1-3 (4-week cycle)] plus capivasertib 400 mg or placebo twice daily (days 2-5, weeks 1-3). PIK3CA/AKT1/PTEN alterations were analysed by retrospective central molecular testing. Dual primary endpoints were OS in the overall population and in patients with PIK3CA/AKT1/PTEN-altered tumours; investigator-assessed PFS was a key secondary endpoint. RESULTS: From July 2019 to February 2022, 812 patients were randomised; 30.7% of patients had PIK3CA/AKT1/PTEN tumour alterations. At final analysis [data cut-off (DCO) 18 March 2024], the median OS for the overall population was 17.7 and 18.0 months with capivasertib-paclitaxel and placebo-paclitaxel, respectively [hazard ratio (HR) 0.92, 95% confidence interval (CI) 0.78-1.08, P = 0.3239] and for patients with PIK3CA/AKT1/PTEN-altered tumours, it was 20.4 months in both arms (HR 1.05, 95% CI 0.77-1.43, P = 0.7602). At PFS DCO (25 May 2022), the median PFS in the overall population numerically favoured capivasertib-paclitaxel (5.6 versus 5.1 months placebo-paclitaxel; HR 0.72, 95% CI 0.61-0.84); this was also the case in patients with PIK3CA/AKT1/PTEN-altered tumours (7.5 versus 5.6 months placebo-paclitaxel; HR 0.70, 95% CI 0.52-0.95). The most frequent adverse event (AE) of grade ≥3 was diarrhoea [12.7% versus 0.7% placebo-paclitaxel (overall population)]. Capivasertib was discontinued due to AEs in 8.5% of patients (4.9% placebo-paclitaxel; overall population); AEs led to death in 4.2% of all patients. CONCLUSIONS: Capivasertib-paclitaxel did not meet the prespecified boundary for improving OS in either population; PFS numerically favoured the combination, especially in PIK3CA/AKT1/PTEN-altered tumours. The safety of capivasertib-paclitaxel was generally manageable and consistent with prior studies.
引用
- Schmid P, McArthur HL, Cortés J, et al. Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial. Ann Oncol. 2025. PMID: 41422862. doi:10.1016/j.annonc.2025.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。